CSL Ltd Annual Report 2019

Privigen ® (10% intravenous Ig) in CIDP in US Hizentra ® (20% subcutaneous Ig) in CIDP in US Hizentra ® (20% subcutaneous Ig) in CIDP in Europe Haegarda ® (C1 Esterase Inhibitor) Subcutaneous in US CSL830 (C1 Esterase Inhibitor) Subcutaneous in EU Privigen ® (10% intravenous Ig) in CIDP in Japan Hizentra ® (20% subcutaneous Ig) in CIDP in Japan Zemaira ® (Alpha1-Proteinase Inhibitor) in US Kcentra ® (Prothrombin Complex Concentrate) for bleeding in Japan AFLURIA ® Quad (quadrivalent egg-based influenza vaccine) FLUCELVAX ® Quadrivalent (quadrivalent cell-based influenza vaccine) FLUAD ® Trivalent (adjuvanted influenza vaccine) FLUAD ® Quadrivalent (adjuvanted influenza vaccine) Research/ pre-clinical Clinical development Registration/ post launch Market development New product development Core capabilities CSL’s R&D pipeline also includes Life Cycle Management projects which address regulatory post marketing commitments, pathogen safety, capacity expansions, yield improvements and new packages and sizes. Immunology & Neurology Haematology & Thrombosis Cardiovascular & Metabolic Transplant Respiratory Vaccines Important advances in 2018/19 * Partnered projects IDELVION ® (rIX-FP) AFSTYLA ® (rFVIII-SingleChain) CSL112 (ApoA-1) in ACS CSL312 (Anti-FXIIa mAb) in HAE CSL842 (C1-INH) for AMR CSL964 (AAT) for GvHD Clazakizumab (Anti-IL-6) for Transplant - Vitaeris* CSL346 (Anti-VEGFBmAb) CSL324 (Anti-G-CSFRmAb) CSL730 (M230) Recombinant Fc - Momenta* CSL334 (Anti-IL-13RmAb) in Atopic Dermatitis - ASLAN* CSL200 (CAL-H) in Sickle Cell Disease CSL787 (Nebulized Ig) CSL889 (Hemopexin) in SCD CSL111 (Anti-Beta Common) in Inflammatory Disease P. Gingivalis POD OH-CRC* Adjuvanted cell culture influenza vaccine (aQIVc) SAM influenza vaccine (novel mRNA-based technology) Our research and development pipeline Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. R&D utilises its expertise in plasma fractionation, recombinant technology, cell and gene therapy and vaccine development to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments that help patients lead full lives. CSL’s strong R&D pipeline includes new treatments that align with its leading-edge technology and commercial capabilities across our therapeutic areas. New products, improved products and manufacturing expertise ensure our continued growth. More on CSL.com (R&D) CSL Limited Annual Report 2019 9